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The effect of remote ischaemic preconditioning on myocardial 
injury in emergency hip fracture surgery (PIXIE trial): phase II 
randomised clinical trial
Sarah Ekeloef,1 Morten Homilius,2 Maiken Stilling,2,3 Peter Ekeloef,4 Seda Koyuncu,5  
Anna-Marie Bloch Münster,6,7 Christian S Meyhoff,8 Ossian Gundel,8,9 Julie Holst-Knudsen,5  
Ole Mathiesen,5 Ismail Gögenur1
AbstrAct
Objective
To investigate whether remote ischaemic 
preconditioning (RIPC) prevents myocardial injury in 
patients undergoing hip fracture surgery.
Design
Phase II, multicentre, randomised, observer blinded, 
clinical trial.
setting
Three Danish university hospitals, 2015-17.
ParticiPants
648 patients with cardiovascular risk factors 
undergoing hip fracture surgery. 286 patients were 
assigned to RIPC and 287 were assigned to standard 
practice (control group).
interventiOn
The RIPC procedure was initiated before surgery with 
a tourniquet applied to the upper arm and consisted 
of four cycles of forearm ischaemia for five minutes 
followed by reperfusion for five minutes.
Main OutcOMe Measures
The original primary outcome was myocardial 
injury within four days of surgery, defined as a peak 
plasma cardiac troponin I concentration of 45 ng/L 
or more caused by ischaemia. The revised primary 
outcome was myocardial injury within four days of 
surgery, defined as a peak plasma cardiac troponin 
I concentration of 45 ng/L or more or high sensitive 
troponin I greater than 24 ng/L (the primary outcome 
was changed owing to availability of testing). 
Secondary outcomes were peak plasma troponin I 
and total troponin I release during the first four days 
after surgery (cardiac and high sensitive troponin I), 
perioperative myocardial infarction, major adverse 
cardiovascular events, and all cause mortality 
within 30 days of surgery, length of postoperative 
stay, and length of stay in the intensive care unit. 
Several planned secondary outcomes will be reported 
elsewhere.
results
573 of the 648 randomised patients were included 
in the intention-to-treat analysis (mean age 79 (SD 
10) years; 399 (70%) women). The primary outcome 
occurred in 25 of 168 (15%) patients in the RIPC 
group and 45 of 158 (28%) in the control group (odds 
ratio 0.44, 95% confidence interval 0.25 to 0.76; 
P=0.003). The revised primary outcome occurred 
in 57 of 286 patients (20%) in the RIPC group and 
90 of 287 (31%) in the control group (0.55, 0.37 to 
0.80; P=0.002). Myocardial infarction occurred in 10 
patients (3%) in the RIPC group and 21 patients (7%) 
in the control group (0.46, 0.21 to 0.99; P=0.04). 
Statistical power was insufficient to draw firm 
conclusions on differences between groups for the 
other clinical secondary outcomes (major adverse 
cardiovascular events, 30 day all cause mortality, 
length of postoperative stay, and length of stay in the 
intensive care unit).
cOnclusiOns
RIPC reduced the risk of myocardial injury and 
infarction after emergency hip fracture surgery. It 
cannot be concluded that RIPC overall prevents major 
adverse cardiovascular events after surgery. The 
findings support larger scale clinical trials to assess 
longer term clinical outcomes and mortality.
trial registratiOn
ClinicalTrials.gov NCT02344797.
Introduction
Worldwide, more than 200 million people undergo 
major non-cardiac surgery annually.1 The average 
overall complication rate is 7% to 11% and the 
30 day mortality is around 0.8% to 1.5%.2 3 At a 
minimum, one third of the postoperative deaths are 
caused by cardiovascular complications.2 In general, 
mortality due to cardiac diseases is decreasing, 
which consequently results in an elderly population 
with a greater number of cardiac comorbidities, 
including ischaemic heart disease, heart failure, and 
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WhAt Is AlreAdy knoWn on thIs topIc
Cardiovascular morbidity is common after non-cardiac surgery, with myocardial 
injury the most prominent outcome
Remote ischaemic preconditioning (RIPC) is an inexpensive intervention that 
could prevent myocardial injury without substantial adverse effects although 
no randomised trial has examined its effect versus standard treatment in non-
cardiac surgery
Myocardial injury is associated with myocardial infarction and short and long 
term mortality, but could be emerging as a separate clinical relevant outcome 
although it is not yet clear how myocardial injury should be managed
WhAt thIs study Adds
RIPC reduced myocardial injury after non-cardiac surgery as well as myocardial 
infarction (the only sufficiently powered secondary outcome); the magnitude of 
this reduction is still uncertain
Further trials including those large enough to reliably measure more established 
cardiovascular diagnoses are needed
This study does not support change in practice
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cardiovascular risk factors.2 In Europe alone, the 
number of patients undergoing surgery in general will 
increase by 25% by 2020 and the elderly population 
will increase by almost 50%.2 In the years to come, 
managing elderly surgical patients with multiple 
cardiovascular comorbidities will be a frequent chal-
lenge in perioperative medicine.
Myocardial injury in non-cardiac surgery (MINS), 
defined as myocardial injury caused by ischaemia, 
has prognostic relevance and occurs during or within 
30 days after non-cardiac surgery.4 Several clinical 
studies have shown MINS to be associated with a 
2-3-fold increased risk of subsequent major adverse 
cardiovascular events and postoperative mortality.4-7 
Thus MINS is recognised as a surrogate for myocardial 
infarction after non-cardiac surgery because patients 
often do not experience ischaemic symptoms after 
surgery.8 In 2018, MINS was established as a diagnosis 
in the fourth universal definition of myocardial 
infarction (European Society of Cardiology clinical 
practice guidelines).9 As MINS is now recognised by the 
European Society of Cardiology,9 it could be emerging 
as a potential diagnosis in its own right. To date no 
intervention has resulted in a reduction in MINS and it 
is a condition that has no agreed treatment.
The well known procedure of remote ischaemic 
preconditioning (RIPC) might protect remote tissues 
and organs from, for example, reperfusion injury.10 
Cycles of forearm ischaemia and reperfusion by the 
inflation of a blood pressure cuff for brief periods is 
the preferred method. The procedure is simple and 
safe and has no known adverse effects in patients 
undergoing elective cardiovascular surgery and in 
those with ST elevation myocardial infarction.10 
The mechanism of RIPC is not fully understood. 
Experimental and clinical studies have suggested that 
the local tissue injury caused by RIPC might activate 
humoral mediators (eg, adenosine, bradykinin, 
antioxidants) and initiate a neuronal signal transfer 
leading to a cytoprotective state but also activation 
of systemic anti-inflammatory and antithrombotic 
mechanisms and endothelial protection.11-14 Sur-
gery is known to activate a severe stress response 
resulting in, for instance, immunological dysfunction, 
hypercoagulability, endothelial dysfunction, and acti-
vation of the sympathetic nervous system, all of which 
are likely to contribute to the pathophysiology of MINS 
and perioperative cardiovascular events.15-17 The 
detrimental systemic effects of surgery therefore might 
potentially be reduced by RIPC.
We carried out a randomised clinical trial (Pre-
vention of Myocardial Injury by Remote Ischaemic 
Preconditioning in Non-cardiac Surgery, PIXIE) to 
test the hypothesis that RIPC compared with standard 
treatment reduces the incidence of myocardial injury 
(primary outcome) after hip fracture surgery.
Methods
trial design
The PIXIE trial was a phase II proof of concept, 
multicentre, randomised, observer blinded, clinical 
trial. All patients received oral and written information 
about the trial and signed an informed consent form 
before inclusion. The trial was reported according to 
the CONSORT statement18 and registered on Clinical-
Trials.gov.
Changes were made to the methods after trial 
commencement. The original primary outcome was 
revised in October 2015 after the start of the trial in 
February 2015. The original primary outcome was 
based on an increase in cardiac troponin I level, 
whereas the revised primary outcome was based on 
an increase in cardiac troponin I or high sensitive 
troponin I level. We modified the outcome because 
a new trial site, Regional Hospital West Jutland, was 
included. This site exclusively assessed high sensitive 
troponin I. The decision to include this trial site was 
independent of the data we had already obtained.
In October 2015 we modified the secondary outcomes 
peak cardiac troponin I and total cardiac troponin I 
release to peak troponin I and total troponin I release 
stratified on cardiac troponin I and high sensitive 
troponin I. This was because of the assessment of high 
sensitive troponin I at Regional Hospital West Jutland.
The trial was initially designed to include patients 
undergoing major emergency abdominal or hip fracture 
surgery. As the recruitment of patients undergoing 
abdominal surgery was challenging in October 2015 
we decided to exclusively include patients undergoing 
hip fracture surgery. The abdominal surgical patients 
already included in the trial were not included in the 
final analysis.
A criterion was added to exclude patients with a new 
fracture of the upper arm, after a small group of such 
patients was identified during screening.
reporting
The secondary outcomes concerning plasma NT-
pro BNP (N-terminal prohormone B type natriuretic 
peptide) and the analyses of a subgroup of patients 
with endothelial dysfunction and biomarkers of 
coagulation are not reported here. We have planned to 
report separately the details of potential mechanisms 
behind the effect of RIPC. Moreover, the long term 
clinical effect of RIPC in the whole cohort will be 
published once data is available. We presented major 
adverse cardiovascular events as a composite outcome 
(as registered in the protocol and on ClinicalTrials.gov) 
and the separate clinical outcomes. We believe that 
the presentation of the separate clinical outcomes is 
informative.
Participants
We included adults aged 45 years or older undergoing 
hip fracture surgery and with a minimum of one of 
four risk factors: ischaemic heart disease, defined 
as angina pectoris, prior myocardial infarction, 
prior percutaneous coronary intervention or prior 
coronary artery bypass grafting; peripheral arterial 
disease, defined as intermittent claudication, reduced 
peripheral arterial blood flow or previous vascular 
surgery due to peripheral arterial disease; previous 
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stroke; and any one of seven cardiovascular risk 
factors (age ≥70 years, congestive heart failure, 
previous transient ischaemic attack, diabetes and 
currently taking an oral hypoglycaemic agent or 
insulin, hypertension, preoperative serum creatinine 
concentration >175 μmol/L, smoking within two 
years of surgery). Exclusion criteria were a history of 
peripheral arterial disease affecting both arms, renal 
failure (estimated glomerular filtration rate <30 mL/
min/1.73m2), cardiogenic shock or cardiac arrest 
during the current hospital stay (before inclusion), 
another operation during the current hospital stay 
(before inclusion), experience of a condition that 
prevented the performance of RIPC, not capable of 
giving informed consent, and previously enrolled in 
the trial. We did not exclude patients who were being 
treated with drugs such as β blockers, dabigatran, 
sulphonamide, or nicorandil. Nor did we exclude 
patients with recent myocardial infarctions or chronic 
ischaemia. Patients were recruited from three Danish 
hospitals, all secondary referral centres, and data were 
collected at the hospitals.
trial randomisation and blinding
Patients were randomly allocated to RIPC or control. A 
third party (a research fellow) generated the random 
allocation sequence using an electronic randomisation 
plan generator (www.randomization.com). The allo-
cation ratio was 1:1 in fixed blocks of six. The nurse 
anaesthetist opened a sealed opaque envelope in 
the operating theatre and allocated the patient 
accordingly. Owing to the nature of the intervention, 
it was not possible to blind the anaesthetist, nurse 
anaesthetist, surgeon (treating clinician), surgical 
staff, and local investigators caring for the patient. The 
cardiologists taking part in the clinical treatment were, 
however, blinded. The principal investigator (SE), who 
determined whether an increase in troponin level was 
ischaemic or non-ischaemic based, was blinded to the 
intervention. Patients receiving regional anaesthesia 
without sedation were not blinded to the allocated 
treatment, whereas patients receiving general 
anaesthesia were blinded to the allocated treatment.
trial intervention
Patients in the control group received standard 
care before, during, and after surgery according to 
local guidelines. Patients in the intervention group 
received the same standard of care along with the 
RIPC procedure. The management did not differ in 
any other way between the two trial groups. The RIPC 
procedure was performed with a tourniquet applied to 
the upper arm and consisted of four cycles of forearm 
ischaemia and reperfusion. The RIPC procedure 
was performed with an electric tourniquet device 
(Tourniquet 4500 ECL; VBM Medizintechnik, Sulz 
am Neckar, Germany). The tourniquet was inflated to 
200 mm Hg for five minutes followed by deflation and 
five minutes of reperfusion. The procedure took 40 
minutes. For patients with a systolic blood pressure 
greater than 185 mm Hg, the tourniquet was inflated 
to a minimum of 15 mm Hg above the patient’s systolic 
blood pressure. The nurse anaesthetist performed the 
RIPC in the operating theatre after induction of general 
or regional anaesthesia. The first round of ischaemia 
and reperfusion was completed before skin incision, 
whereas the remaining rounds could be performed 
during surgery. The intervention was considered 
complete when all four cycles had been administered. 
To standardise the RIPC, the investigators instructed 
the nurse anaesthetists on how to perform the 
procedure. The exact time of each cycle, technical 
difficulties, and disruptions were noted. The choice 
of anaesthesia and analgesia was left to the treating 
anaesthesiologist. Perioperative and postoperative 
care followed the departments’ standard protocol.
trial outcomes
Troponin I was collected soon before surgery and in the 
morning on postoperative days 1 (the morning of the first 
postoperative day) to 4. An increase in troponin I was 
defined as a cardiac troponin I concentration of 45 ng/L 
or more or high sensitive troponin I concentration 
greater than 24 ng/L. If the levels were raised, a 
minimum of one electrocardiographic procedure was 
performed irrespective of symptoms and the patient 
was evaluated for the presence of an ischaemic or non-
ischaemic event to explain the increased troponin I. A 
cardiologist was consulted if necessary. Research staff 
collected data prospectively, and follow-up at 30 days 
was carried out by review of the electronic medical 
records in each of the hospitals. The Danish electronic 
medical records are automatically updated on vital 
status within days of death.
Primary outcomes
The prespecified primary outcome as stated in the 
original registration and protocol was MINS within 
four days of hip fracture surgery. MINS is a surrogate 
for myocardial infarction after non-cardiac surgery 
but might be emerging as a separate clinical relevant 
outcome.9 19 The original primary outcome, MINS, 
was defined as a peak plasma cardiac troponin I 
concentration of 45 ng/L or more, whereas the revised 
primary outcome was defined as a peak plasma cardiac 
troponin I concentration of 45 ng/L or more or high 
sensitive troponin I greater than 24 ng/L. The blinded 
primary investigator (SE) excluded non-ischaemic 
causes of raised troponin levels—for example, sepsis, 
pulmonary embolus, rapid atrial fibrillation, chronic 
raised troponin level. Patients had to have a minimum 
of two postoperative troponin assessments within four 
days of surgery. If levels were raised above the limits 
before surgery (baseline), an increase of minimum 
20% from the baseline troponin I level was required 
for the diagnosis of MINS.
Two hospitals (Zealand University Hospital and 
Herlev Hospital) assessed cardiac troponin I using the 
Healthcare Dimension Vista assay (Siemens, Munich, 
Germany) with a cut-off of 45 ng/L or more (99th centile 
upper reference limit, 10% coefficient of variation at 
40 ng/L), and one hospital (Regional Hospital West 
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Jutland) assessed high sensitive troponin I using an 
Abbott assay (Abbott, IL) with a cut-off greater than 
24 ng/L (99th centile upper reference limit, 14% 
coefficient of variation).
secondary outcomes
Several secondary outcome measures were included. 
(1) peak plasma troponin I and total troponin I release 
(area under the curve) during surgery or during the first 
four days after surgery stratified on cardiac troponin I 
and high sensitive troponin I. (2) Perioperative myo-
cardial infarction (universal definition of myocardial 
infarction, published in 201220) defined by (A) a 
typical increase or decrease in cardiac troponin I level 
with peak plasma cardiac troponin I of 45 ng/L or more 
(99th centile upper reference limit, 10% coefficient of 
variation at 40 ng/L) (Regional Hospital West Jutland 
high sensitive troponin I >24 ng/L), and with at least 
one of the following: symptoms of ischaemia, new or 
presumed new ST segment T wave changes or new 
left bundle branch block, development of ischaemic 
Q waves in the electrocardiogram, imaging evidence 
of new loss of viable myocardium or new regional 
wall motion abnormality or identification of an 
intracoronary thrombus by angiography or autopsy. 
(B) Cardiac related death with symptoms suggestive of 
myocardial ischaemia and presumed new ischaemic 
electrocardiographic changes or new left bundle 
branch block, but death occurred before cardiac 
biomarkers were obtained or before cardiac biomarker 
values would be increased. (C) Development of new 
ischaemia related Q waves on an electrocardiogram 
or other electrocardiographic findings of a healing 
myocardial infarction if troponin levels were obtained 
at times that could have missed the clinical event. 
(3) Major adverse cardiovascular events within 30 
days of surgery defined as non-fatal cardiac arrest, 
coronary revascularisation procedure (percutaneous 
coronary intervention or coronary artery bypass graft), 
acute coronary syndrome, stroke, congestive heart 
failure, new clinically important cardiac arrhythmia, 
peripheral arterial thrombosis, or readmission to 
hospital for cardiovascular reasons. (4) Length of 
postoperative hospital stay. (5) Length of stay on an 
intensive care unit. (6) All cause mortality at 30 days 
(cardiovascular or non-cardiovascular cause, with the 
latter clearly documented).
The primary investigator (SE) blinded to the treat-
ment allocation determined whether an increase in 
troponin level was ischaemic related (the lack of a 
non-ischaemic event) or non-ischaemic related, and 
whether a death was related to a cardiovascular or non-
cardiovascular cause. During the hospital admission, 
patients were observed for local adverse effects of RIPC, 
including pain in the upper arm, sensory disturbances, 
and local skin irritation.
sample size
In a large cohort study performed by the VISION 
(Vascular Events In Noncardiac Surgery Patients 
Cohort Evaluation) investigator group, 8.0% of the 
patients undergoing non-cardiac surgery experienced 
MINS.4 In our trial, PIXIE, we included patients with 
a moderate to high risk of MINS, whereas the VISION 
study4 included patients at all risk levels. We assumed 
that 15% of the patients in the control group would 
experience MINS and assumed that RIPC would reduce 
the event rate of MINS to 7%. With a risk of a type I error 
of 5% and a type II error of 20%, we calculated that 
264 patients in each group would provide adequate 
power to detect a difference of 8%.
statistical analysis
All patients with an evaluable primary outcome, MINS 
within four days of surgery, were included in the 
intention-to-treat analysis regardless of whether they 
received the allocated treatment. The intention-to-treat 
analysis was the primary analysis of the PIXIE trial. 
Patients included in the per protocol analysis received 
the allocated treatment and had an evaluable primary 
outcome.
We used the χ2 test to compare the event rates 
of MINS, major adverse cardiovascular events and 
the individual cardiovascular events, and all cause 
mortality. Troponin I release from baseline to day 4 
after surgery was calculated separately for the two 
different troponin I assays by the means of area under 
the curve. Peak troponin I, area under the curve 
troponin I, and length of stay in the intensive care 
unit were expressed as median (interquartile range) 
and analysed with a Wilcoxon two sample test. Length 
of stay was expressed as mean (95% confidence 
interval) and compared with an unpaired t test. 
Moreover, we compared the event rate of increased 
troponin I levels, ischaemic and non-ischaemic, in 
both treatment groups with the χ2 test. Univariable 
and multivariable logistic regressions were used to 
analyse the association between the intervention and 
MINS (revised primary outcome). The multivariable 
analysis was adjusted for predefined variables, 
including age group, sex, ischaemic heart disease, 
stroke, congestive heart failure, peripheral arterial 
disease, diabetes, acetylsalicylic acid, type of 
anaesthesia, number of measurements for troponin 
I, and trial site. We tested potential predefined 
interactions between age group and sex, intervention 
and type of anaesthesia, and intervention and trial 
site. None were statistically significant (P<0.05) and 
therefore not included in the final analysis. To avoid 
overfitting of the model we included a maximum of 
one variable for every 10 events in the multivariable 
logistic regression. The goodness of fit for the 
multivariable logistic regression was tested with a 
Hosmer and Lemeshow test.
We performed two post hoc subgroup analyses. We 
analysed the effect of RIPC on MINS in patients who 
received or did not receive propofol for sedation, 
induction, or maintenance of anaesthesia. Moreover, 
we analysed the effect of RIPC in patients undergoing 
general anaesthesia compared with regional anaes-
thesia. Statistical analyses were performed in SAS 
version 9.4 (SAS Institute) and graphics were created 
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in GraphPad Prism version 6. We considered a two 
sided P value <0.05 to be significant.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, 
or implementation of the study. No patients were asked 
to advice on interpretation or writing up the results. 
All participants will be informed of the trial results 
by mail. The trial results will be disseminated to the 
public through online science media.
results
Patient flow and baseline characteristics
Recruitment took place between February 2015 and 
September 2017. The last follow-up was in October 
2017. Figure 1 shows the flow of participants 
through the trial. Among 648 randomised patients, 
573 patients were included in the intention-to-treat 
analysis (Zealand University Hospital n=281, Herlev 
Hospital n=45, Regional Hospital West Jutland n=247) 
and 559 patients in the per protocol analysis.
Table 1 shows the characteristics of the study 
population. Most of the patients were women, with a 
mean age of 78.8 (SD 10.1) years in the RIPC group 
and 79.2 (9.8) years in the control group. In both 
groups, hypertension and hypercholesterolaemia 
were the most common cardiovascular comorbidities, 
and 15% (43/286) of patients in the RIPC group and 
15% (42/287) in the control group had a history of 
ischaemic heart disease. The groups were similar for 
preoperative drug treatment except for acetylsalicylic 
acid, which was more commonly used in the RIPC 
group compared with control group (25% (71/286) v 
17% (48/287); P=0.02). Perioperative characteristics 
were similar between the groups (table 2).
None of the patients experienced any local adverse 
effects of RIPC. Eight out of 316 patients allocated to 
RIPC (2%) did not complete the procedure owing to 
discomfort and nine out of 316 patients (3%) did not 
complete the procedure owing to technical difficulties 
(fig 1).
Primary outcomes
The original primary outcome occurred in 25 out 
of 168 patients (15%) in the RIPC group and 45 out 
of 158 (28%) in the control group (odds ratio 0.44, 
95% confidence interval 0.25 to 0.76; P=0.003). The 
revised primary outcome occurred in 57 out of 286 
patients (20%) in the RIPC group and in 90 out of 
287 (31%) in the control group (0.55, 0.37 to 0.80; 
P=0.002). When including both ischaemic and non-
ischaemic increases in troponin levels, 69 out of 286 
patients (24%) had raised troponin levels in the RIPC 
group and 103 out of 287 (36%) in the control group, 
Assessed for eligibility
Excluded
Declined to participate
Unable to provide informed consent
Renal failure
Previous inclusion in trial
Conditions prevent performance of RIPC
Cardiogenic shock or cardiac arrest
64
253
29
1
25
1
Allocated to RIPC
Received allocated intervention
Did not receive allocated intervention
  Discomfort
  Technical difficulties
299
17
8
9
Lost to follow-up†
373
22
Lost to follow-up†
30
1021
Randomised*
648
316
Received allocated intervention
Did not receive allocated intervention
309
0
309
Allocated to control
Intention to treat
Per protocol
287
287
Analysed
Intention to treat
Per protocol
286
272
Analysed
Fig 1 | Flow of participants through study. *includes 23 patients undergoing emergency abdominal surgery (patients 
were excluded from analyses and final part of flow chart). †no evaluable primary outcome. riPc=remote ischaemic 
preconditioning
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characteristics riPc group (n=286) control group (n=287)
Mean (SD) age (years) 78.8 (10.1) 79.2 (9.8)
Women 199 (70) 200 (70)
Mean (SD) body mass index 23.4 (4.2) 23.9 (4.3)
Smoker:    
 No 124 (43) 118 (41)
 Current 93 (32) 76 (26)
 Former 69 (24) 93 (32)
Alcohol consumption*:    
 None 58 (20) 58 (20)
 <limit 188 (66) 185 (64)
 >limit 40 (14) 44 (15)
Mean (SD) preoperative blood pressure (mm Hg):
 Systolic 145.4 (24.9) 146.8 (22.6)
 Diastolic 75.8 (14.9) 76.5 (14.2)
ASA score†:    
 I-II 164 (57) 167 (58)
 III-IV 122 (43) 120 (42)
Revised cardiac risk index‡:    
 I-II 256 (89) 255 (89)
 III-IV 30 (10) 32 (11)
Median (interquartile range) preoperative troponin I level (ng/L):
 Cardiac 15.0 (15.0-30.0) 15.0 (15.0-34.5)
 High sensitive 10.0 (10.0-23.0) 10.5 (10.0-25.0)
Mean (SD) No of postoperative troponin I measurements:    
 2 40 (14.0) 28 (9.8)
 3 67 (23.4) 65 (22.6)
 4 179 (62.6) 194 (67.6)
Mean (SD) timing of troponin I measurements (hours after surgery):    
 1 19.5 (4.7) 19.4 (4.4)
 2 43.3 (4.4) 43.1 (4.5)
 3 67.2 (4.6) 67.0 (4.8)
 4 91.1 (5.0) 90.8 (5.6)
Mean (SD) preoperative haemoglobin (g/L) 126.9 (15.5) 127.9 (16.6)
Median (interquartile range) creatinine (mg/dL):    
 Preoperative 0.75 (0.60-0.98) 0.80 (0.63-1.03)
 Postoperative:
  Day 1 0.75 (0.59-0.92) 0.75 (0.62-0.96)
  Day 2 0.72 (0.58-0.95) 0.64 (0.71-1.01)
  Day 3 0.70 (0.57-0.90) 0.75 (0.58-0.95)
  Day 4 0.69 (0.58-0.89) 0.73 (0.57-0.94)
Median (interquartile range) eGFR (mL/min/1.73m2):    
 Preoperative 81.0 (60.0-90.0) 78.0 (57.0-90.0)
 Postoperative:
  Day 1 80.0 (63.0-90.0) 80.0 (60.0-90.0)
  Day 2 82.0 (63.0-90.0) 80.0 (58.0-90.0)
  Day 3 85.0 (67.0-90.0) 82.0 (63.0-90.0)
  Day 4 84.5 (66.0-90.0) 81.5 (62.0-90.0)
Comorbidities:    
 Ischaemic heart disease 43 (15) 42 (15)
 Peripheral arterial disease 18 (6) 19 (7)
 Stroke 44 (15) 44 (15)
 Congestive heart failure 26 (9) 25 (9)
 Transient cerebral ischaemia 18 (6) 11 (4)
 Diabetes 39 (14) 37 (13)
 Hypertension 176 (61) 195 (68)
 Hypercholesterolaemia 90 (31) 89 (31)
 Chronic kidney disease 14 (5) 8 (3)
 Atrial fibrillation 62 (22) 54 (19)
 Chronic obstructive pulmonary disease 57 (20) 56 (19)
 Cancer 18 (6) 21 (7)
Preoperative drugs:    
 Acetylsalicylic acid§ 71 (25) 48 (17)
 Platelet inhibitors 27 (9) 26 (9)
 Vitamin K antagonist 29 (10) 31 (11)
 DOAC 17 (6) 21 (7)
 β blocker 69 (24) 78 (27)
table 1 | baseline characteristics of patients assigned to remote ischaemic preconditioning (riPc) or standard practice 
(control). values are numbers (percentages) unless stated otherwise
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P=0.002. Supplementary table 1 lists the causes of 
non-ischaemic increases in troponin levels. The timing 
and number of measurements for troponin I did not 
differ between the groups (table 1, supplementary 
table 2). In the RIPC group, an unadjusted subgroup 
analysis showed that the incidence of MINS was 
significantly reduced in the group that received 
propofol compared with the group that did not receive 
propofol (40/231 patients (17%) v 17/55 patients 
(31%); odds ratio 0.47, 95% confidence interval 0.24 
to 0.91; P=0.03). No difference was found when the 
effect of RIPC on preventing MINS was analysed in 
patients receiving general anaesthesia compared with 
regional anaesthesia (29/142 patients (20%) v 28/144 
patients (19%), 0.94, 0.53 to 1.7; P=0.84).
secondary outcomes
Peak troponin I and total troponin I release stratified 
on cardiac troponin I and high sensitive troponin I 
were statistically similar in the intervention groups 
(table 3). In the RIPC group, 3% (10/286) of patients 
experienced a perioperative myocardial infarction 
within 30 days of surgery compared with 7% (21/287) 
in the control group (odds ratio 0.46, 95% confidence 
interval 0.21 to 0.99; P=0.04). No statistically 
significant difference was found between the groups 
for major adverse cardiovascular events within 30 
days of surgery, hospital length of stay, length of 
stay in the intensive care unit, or 30 day all cause 
mortality (table 3). The per protocol analyses showed 
similar results (supplementary tables 3 and 4). A 
multivariable logistic regression analysis adjusted 
for sex, age group, use of acetylsalicylic acid, number 
of postoperative troponin I measurements, type of 
anaesthesia, study site, pre-existing congestive heart 
failure, former stroke, pre-existing ischaemic heart 
disease, pre-existing peripheral vascular disease, and 
pre-existing diabetes mellitus showed a significant 
association between the intervention with RIPC and a 
reduced risk of MINS (adjusted odds ratio 0.54, 95% 
confidence interval 0.35 to 0.81; P=0.003). Figure 
2 shows the results of the multivariable analysis 
(see supplementary table 5 for the results of the 
univariable and multivariable logistic regressions). 
The multivariable logistic regression showed no 
interaction between age group and sex (P=0.39), 
intervention and type of anaesthesia (P=0.24), and 
intervention and trial site (P=0.21).
table 2 | Perioperative characteristics of patients assigned to remote ischaemic preconditioning (riPc) or standard 
practice (control). values are numbers (percentages) unless stated otherwise
characteristics riPc group (n=286) control group (n=287)
Surgical procedure:    
 Internal fixation 130 (45) 116 (40)
 Intramedullary rod 57 (20) 76 (26)
 Hemi hip replacement 51 (18) 42 (15)
 Total hip replacement 48 (17) 53 (18)
Median (interquartile range) duration of surgery (mins) 57.0 (40.0-74.0) 60.0 (45.0-82.0)
Anaesthesia:    
 Epidural 103 (36) 83 (29)
 Spinal 41 (14) 58 (20)
 Total intravenous 36 (13) 37 (13)
 Inhalational 106 (37) 109 (38)
Propofol use:    
 General anaesthesia induction 95 (33) 97 (34)
 General anaesthesia induction and maintenance 36 (13) 37 (13)
 Sedation 100 (35) 92 (32)
Median (interquartile range) propofol dose (mg) 120.0 (80.0-207.5) 111.0 (72.7-230.0)
Median (interquartile range) blood loss (mL) 150.0 (50.0-250.0) 150.0 (50.0-300.0)
Transfusion 14 (5) 15 (5)
Median (interquartile range) transfusion volume (mL) 400.0 (300.0-600.0) 300.0 (284.3-600.0)
Median (interquartile range) systolic blood pressure <100 mm Hg (mins) 35.0 (22.0-60.0) 44.5 (22.0-70.0)
characteristics riPc group (n=286) control group (n=287)
 Calcium antagonist 70 (24) 81 (28)
 ACE inhibitor or ARB 113 (39) 123 (43)
 Diuretics 108 (38) 118 (41)
 Statin 89 (31) 89 (31)
 Isosorbide mononitrate 15 (5) 8 (3)
 Antidiabetics 24 (8) 21 (7)
 Insulin 20 (7) 19 (7)
ACE=angiotensin-converting enzyme; ASA=American Society of Anesthesiologists; ARB=angiotensin II receptor blocker; DOAC=direct oral anticoagulant; 
eGFR=estimated glomerular filtration rate.
*≤7 units/week for women and ≤14 units/week for men.
†Score of physical health. I-II: good physical health. III-IV: poor physical health.
‡Score of postoperative risk of cardiac complications. I-II: low risk. III-IV: high risk.
§P=0.02.
table 1 | continued
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discussion
In this phase II multicentre, randomised, observer 
blinded, clinical trial including 573 patients under-
going hip fracture surgery, remote ischaemic precon-
ditioning (RIPC) reduced the incidence of myocardial 
injury from 28% to 15% (odds ratio 0.44, 95% 
confidence interval 0.25 to 0.76) and myocardial 
infarction within 30 days of surgery from 7% to 
3% (0.46, 0.21 to 0.99). In recent years, several 
preventive strategies have been examined to reduce 
the risk of myocardial infarction and major adverse 
cardiovascular events in non-cardiac surgery.21-23 In 
this trial we show an effective, simple, and clinically 
applicable perioperative method to reduce the risk of 
myocardial injury.
comparison with other studies
RIPC has been known since the 1990s when a study 
found that brief episodes of ischaemia to one part of 
canine myocardium protected remote myocardium 
from ischaemia and reperfusion injury.24 Since then 
several randomised clinical trials have reported an 
effect of RIPC on reducing myocardial reperfusion injury 
and major adverse cardiovascular events in patients 
with ST elevation myocardial infarction undergoing 
primary percutaneous coronary intervention.25-28 Re-
cent studies investigating the effect of RIPC in patients 
undergoing cardiac surgery did not find any effect of 
RIPC on the clinical outcomes, including myocardial 
infarction and postoperative mortality, despite phase 
II randomised clinical trials finding a reduced overall 
postoperative troponin-T release in the RIPC group.29-31
strengths and limitations of this study
At the study sites, assessments of troponin I were 
usual clinical practice. In the literature, the definition 
of myocardial injury in non-cardiac surgery (MINS) 
is based on troponin T.32 33 In our trial, we chose 
to define the MINS threshold as the 99th centile of 
the upper reference limit for each of the troponin 
I assays. This approach is in accordance with the 
clinical practice guidelines by the European Society 
of Cardiology.9 The threshold could potentially be 
too low to have prognostic importance and MINS 
might be overestimated in both groups. MINS defined 
by high sensitive troponin I level was slightly more 
sensitive than MINS defined by cardiac troponin I 
level, which could explain the high rate of MINS in 
our study, but the multivariable regression analysis 
showed no statistically significant difference between 
the trial sites. A Scandinavian study examined the 
incidence of a raised troponin T level as a sign of MINS 
in patients undergoing hip fracture surgery.5 The 
diagnosis of MINS was based on the fourth generation 
troponin T threshold. The study reported that 31% of 
the patients experienced MINS within two days of 
surgery, which is similar to the incidence of MINS in 
our control group.5 Patients with hip fractures are at 
table 3 | Primary and secondary outcomes in patients assigned to remote ischaemic preconditioning (riPc) or standard 
practice (control). values are numbers (percentages) unless stated otherwise
Outcomes riPc group (n=286)
control group  
(n=287) Odds ratio (95% ci) P value
MINS:
Original primary outcome (n=326) 25/168 (15) 45/158 (28) 0.44 (0.25 to 0.76) 0.003
Revised primary outcome (n=573) 57/286 (20) 90/287 (31) 0.55 (0.37 to 0.80) 0.002
Peak troponin I level (ng/L):
Median (interquartile range) cardiac  
troponin I (n=326)
22.0 (15.0-49.50) 27.5 (15.0-102.0)   0.27
Median (interquartile range) high  
sensitive troponin I (n=247)
17.0 (10.0-43.0) 24.0 (10.0-54.0)   0.17
Area under curve (ng/L/h):
Median (interquartile range)  
cardiac troponin I (n=326)
1518.0 (1380.0-2928.0) 1776.0 (1380.0-4632.0)   0.09
Median (interquartile range)  
high sensitive troponin I (n=247)
996.0 (960.0-2436.0) 1224.0 (960.0-3540.0)   0.12
MACE* 27 (9) 36 (12) 0.73 (0.43 to 1.23) 0.24
Myocardial infarction 10 (3) 21 (7) 0.46 (0.21 to 0.99) 0.04
Stroke 3 (1) 6 (2) 0.50 (0.12 to 2.00) 0.50
Congestive heart failure 3 (1) 5 (2) 0.60 (0.14 to 2.53) 0.72
Peripheral arterial disease 0 (0) 1 (0.3)   1.00
Percutaneous coronary intervention 0 (0) 3 (1)   0.25
CABG 0 (0) 0 (0)   1.00
Clinically important arrhythmia 15 (5) 11 (4) 1.39 (0.63 to 3.08) 0.42
Non-fatal cardiac arrest 1 (0.3) 2 (1) 0.50 (0.045 to 5.55) 0.37
Cardiovascular mortality 2 (1) 4 (1) 0.50 (0.09 to 2.74) 0.69
Cardiovascular hospital readmission 3 (1) 2 (1) 1.51 (0.25 to 9.11) 0.69
Mean (95% CI) length of stay (days) 7.1 (6.7 to 7.5) 7.2 (5.0 to 7.7) - 0.74
Median (interquartile range)  
length of stay in ICU (days)
1.0 (0.5-5.5) 1.0 (0.5-2.0) - 1.00
30 day all cause mortality 5 (2) 9 (3) 0.55 (0.18 to 1.66) 0.29
MINS=Myocardial injury in non-cardiac surgery; MACE=major adverse cardiovascular events; CABG=coronary artery bypass grafting; ICU=intensive care 
unit.
*Myocardial infarction, non-fatal cardiac arrest, stroke, primary percutaneous coronary intervention, coronary artery bypass grafting, cardiovascular 
readmission to hospital, peripheral arterial disease, congestive heart failure, clinically important arrhythmia, and cardiovascular mortality.
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high risk of cardiovascular events when undergoing 
an urgent major orthopaedic procedure. This could 
provide a possible explanation for the high rate of 
MINS.
We performed separate analyses to account for the 
different types of assays for troponin I. The analysis of 
high sensitive troponin I included 247 patients and the 
analysis of cardiac troponin I included 326 patients. 
We found lower point estimates in the RIPC group 
compared with the control group, but the interquartile 
ranges were wide. The lack of difference between 
the groups might reflect low statistical power or that 
an increase in troponin in MINS reflects a different 
pathophysiology from that in patients with myocardial 
infarction.
About one third of the patients had one or more 
missing troponin I measurements; mostly for the 
third or fourth postoperative measurement. Large 
observational studies have shown that MINS primarily 
occurs within postoperative day 2.4 33 The risk of 
overlooking MINS because of a missing troponin I 
measurement should be small.
More patients in the RIPC group than control 
group received acetylsalicylic acid, but an unplanned 
analysis showed that the drug was not significantly 
associated with a reduced risk of MINS.
Propofol was the main agent used for intravenous 
sedation. In cardiac surgery and experimental studies 
propofol has been discussed as interfering and 
inhibiting the cardioprotective effects of RIPC.34 In our 
trial, about 80% of the patients received intravenous 
propofol and we found no interaction between type 
of anaesthesia and RIPC. The trial was not, however, 
designed to draw any conclusions on this matter. The 
potential interaction between anaesthetic regimen 
and the effect of RIPC is debatable. Results from meta-
analyses and clinical studies are contradictory and 
primarily from cardiac surgery.29 30 35 36 To the best 
of our knowledge, no clinical trial has specifically 
investigated the influence of an anaesthetic regimen 
on the effect of RIPC.
Our trial design was pragmatic to ease its imple-
mentation in the clinical setting, thus the anaesthetic 
regimen was not standardised. The surgical procedure 
RIPC
Male sex
Age:
  <75 years
  75-84 years
  ≥85 years
Acetylsalicylic acid
No of PO troponin I measurements:
  4 
  3 
  2 
Anaesthesia:
  Inhalational
  Total intravenous
  Epidural
  Spinal
Study site:
  A
  B
  C
Comorbidities:
  Congestive heart failure
  Stroke
  Ischaemic heart disease
  Peripheral arterial disease
  Diabetes 
0.54 (0.35 to 0.81)
0.89 (0.56 to 1.42)
1.00 (reference)
2.39 (1.34 to 4.29)
4.54 (2.56 to 8.07)
1.27 (0.76 to 2.13)
1.00 (reference)
0.66 (0.39 to 1.11)
0.80 (0.42 to 1.51)
1.00 (reference)
0.25 (0.10 to 0.63)
0.84 (0.51 to 1.40)
1.04 (0.59 to 1.83)
1.00 (reference)
1.39 (0.60 to 3.23)
1.65 (1.06 to 2.59)
1.40 (0.67 to 2.89)
1.66 (0.97 to 2.87)
1.20 (0.65 to 2.24)
0.71 (0.30 to 1.65)
1.13 (0.62 to 2.07)
0 1 2 4 53 6 8 97 10
Decreased
risk of MINS
Increased
risk of MINS
Adjusted odds
ratio (95% CI)
Adjusted odds
ratio (95% CI)
Fig 2 | Forest plot of multivariable logistic regression. riPc=remote ischaemic preconditioning; PO=postoperative; 
Mins=myocardial injury in non-cardiac surgery
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and preoperative and postoperative care (for example, 
treatment of preoperative and postoperative pain, 
fluids, blood transfusions, and physiotherapy) followed 
national guidelines, but with local variations in each of 
the trial sites. The trial sites had a standardised clinical 
guideline for patients with hip fractures based on the 
Danish national guidelines.37 The pragmatic design 
increases the generalisability of the trial.
The diagnosis of MINS has only recently been 
defined and no established international consensus on 
treatment exists. The management of MINS is therefore 
not clear.
Although we observed no local adverse effects of 
RIPC, the trial is too small to draw any conclusions on 
safety. A randomised clinical trial in cardiac surgery 
reported that 35 out of 801 patients (4.4%) had 
transient skin petechiae during RIPC, and no patients 
had any adverse effects with long term consequences.30 
At one year follow-up, the occurrence of clinical 
adverse events including death and readmission did 
not differ between the RIPC group and control group.30 
In vascular surgery, RIPC has been reported to reduce 
kidney impairment and intestinal and pulmonary 
injury.38 39
Our study was not powered to draw conclusions on 
the secondary outcomes, therefore the effect of RIPC 
on clinical outcomes needs to be replicated in a larger 
trial. We are currently collecting data on long term 
clinical outcomes and mortality.
conclusions and future implications
In this randomised clinical trial, RIPC reduced the risk 
of myocardial injury within four days and myocardial 
infarction within 30 days of hip fracture surgery. We 
cannot, however, conclude that RIPC overall prevents 
major adverse cardiovascular events and other 
clinically important outcomes after surgery. Future 
studies should elaborate on these outcomes and 
the clinical cardiovascular effect of RIPC in the non-
cardiac surgical setting.
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